Espicom


The Pharmaceutical Market: Indonesia

Published 22 December 2014

  • 143 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
The Pharmaceutical Market: Indonesia

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
13
Business Environment
15
Industry Forecast
16
Pharmaceutical Market Forecast
16
Table: Pharmaceutical Sales, Historical Data And Forecasts
18
Healthcare Market Forecast
19
Table: Healthcare Expenditure Trends, Historical Data And Forecasts
20
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts
21
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts
22
Prescription Drug Market Forecast
23
Table: Prescription Drug Market Indicators, Historical Data And Forecasts
24
Patented Drug Market Forecast
25
Table: Patented Drug Market Indicators, Historical Data And Forecasts
26
Generic Drug Market Forecast
27
Table: Generic Drug Market Indicators, Historical Data And Forecasts
28
OTC Medicine Market Forecast
29
Table: OTC Medicine Sales By Category, 2004-2010
30
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts
31
Pharmaceutical Trade Forecast
32
Table: Pharmaceutical Trade Data And Forecast (US$mn)
34
Table: Pharmaceutical Trade Data And Forecasts (IDRmn)
34
Other Healthcare Data
35
Key Risks To BMI's Forecast Scenario
35
Macroeconomic Forecasts
37
Export Ban Hits Hard
38
Prabowo Raising The Stakes With Protectionist Stance
39
Mixed Picture For Investment Outlook
40
Table: Economic Activity (Indonesia 2009-2018)
41
Industry Risk Reward Ratings
42
Asia Pacific Risk/Reward Ratings
42
Indonesia Risk/Reward Ratings
48
Rewards
48
Risks
49
Market Overview
50
Industry Trends And Developments
51
Epidemiology
51
Non-Communicable Diseases
51
Communicable Diseases
52
HIV/AIDS
53
Public Health Developments
54
Table: UN Millennium Development Goals For Indonesia
54
Healthcare System
55
Health Insurance
57
Health Insurance Developments
59
Healthcare System Reform
60
Medical Tourism
61
Research & Development
61
Clinical Trials
62
Herbal Medicines
63
Regulatory Development
65
Pharmaceutical Advertising
67
Regional Harmonisation
68
Intellectual Property Issues
69
Halal Medicine Regulations
72
Labelling Requirements
73
Compulsory Licensing
73
Counterfeit Drugs
74
Generic Drug Legislation
75
Free Trade Agreements
76
Pricing Regime
76
Reimbursement Regime
78
Competitive Landscape
79
Pharmaceutical Industry
79
Table: Selected List Of Pharmaceutical Business Areas With Restricted Conditions
80
Table: Top-10 Pharmaceutical Companies According To Market Capitalisation
81
Domestic Industry
81
Foreign Industry
83
Recent Pharmaceutical Industry Developments
83
Pharmaceutical Wholesale
84
Pharmaceutical Retail
85
Company Profile
88
Soho Group
88
Darya-Varia Group
91
PT Kalbe Farma
94
PT Biofarma
98
Kimia Farma
102
Combiphar PT
106
Indopharma
108
Sanofi
111
Pfizer
114
Novartis
117
GlaxoSmithKline
120
Merck & Co
123
Bayer
126
Merck Group
129
Demographic Forecast
132
Table: Indonesia's Population By Age Group, 1990-2020 ('000)
133
Table: Indonesia's Population By Age Group, 1990-2020 (% of total)
134
Table: Indonesia's Key Population Ratios, 1990-2020
135
Table: Indonesia's Rural And Urban Population, 1990-2020
135
Glossary
136
Methodology
138
Pharmaceutical Expenditure Forecast Model
138
Healthcare Expenditure Forecast Model
138
Notes On Methodology
139
Risk/Reward Ratings Methodology
140
Ratings Overview
141
Table: Pharmaceutical Risk/Reward Ratings Indicators
141
Indicator Weightings
142
OVERVIEW OF THE PHARMACEUTICAL MARKET IN INDONESIA

Indonesia's new goal to establish universal healthcare coverage by 2019 rather than 2014 is more feasible given that the programme will be rolled out in phases. We continue to see universal healthcare coverage as a key theme in Asia, although poor governance in several countries across the region will delayitsimplementation. Despite this, pharmaceutical firms will continue to enjoy strong growth in the region due to the expanding, increasingly ageing and affluent population, which will boost volume demand for pharmaceuticals as well as medical services across the board.

HeadlineExpenditure Projections

Pharmaceuticals: IDR53,041bn (US$6.04bn) in 2011 to IDR58,657bn (US$6.25bn) in 2012; +10.6% growth in local currency terms and +3.5% in US dollar terms. Local currency forecastbroadlyunchanged from previous quarter.

Healthcare: IDR195,355bn (US$22.26bn) in 2011 to IDR223,454bn (US$23.82bn) in 2012; +14.4% growth in local currency terms and +7.0% in US dollar terms. Local currency forecastunchanged from previous quarter.

Medicaldevices: IDR5,721bn (US$652mn) in 2011 to IDR6,282bn (US$670mn) in 2012; +9.8% growth in local currency terms and +2.7% in US dollar terms. Local currency forecastbroadlyunchanged from previous quarter.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%